ConductScience.org, home

Paper36600271

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.

Yang F and 7 others. J Exp Clin Cancer Res, 2023. Cited by 62 papers, by iCite.

Cite this record

ConductScience Library. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. Papers, record 36600271. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36600271

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
PubMed
Journal
J Exp Clin Cancer Res
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
62
iCite
Relative citation ratio, by iCite
5.05
iCite
Revised in PubMed
2023-02-24
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yang FFan
2Shay CChloe
3Abousaud MMarin
4Tang CChris
5Li YYamin
6Qin ZZhaohui
7Saba NFNabil F
8Teng YYonghttps://orcid.org/0000-0002-1856-7289

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, ImmunologicalMajor topic
Drug-Related Side Effects and Adverse ReactionsMajor topic
Immune Checkpoint InhibitorsMajor topic
Lung NeoplasmsMajor topic
Female
Humans
Male
Immunotherapy
United States
Adolescent
Young Adult
Adult
Middle Aged
Aged
Aged, 80 and over

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R03 DE028387NIDCR NIH HHSUnited StatesR03DE028387PubMed and NIHNIH RePORTER
R01DE028351NIDCR NIH HHSUnited StatesR01DE028351PubMed and NIHNIH RePORTER
R03 DE032084NIDCR NIH HHSUnited StatesR03DE032084PubMed and NIHNIH RePORTER
R01 DE028351NIDCR NIH HHSUnited StatesR01DE028351PubMed and NIHNIH RePORTER
R03DE032084NIDCR NIH HHSUnited StatesR03DE032084PubMed and NIHNIH RePORTER

Download CSV of grants

References71

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133645548Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.J Clin Invest2021https://conductscience.org/library/papers/33645548PubMed
232127660Trends in clinical development for PD-1/PD-L1 inhibitors.Nat Rev Drug Discov2020https://conductscience.org/library/papers/32127660PubMed
328975219Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.JAMA Oncol2018https://conductscience.org/library/papers/28975219PubMed
430586539The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.Discov Med2018https://conductscience.org/library/papers/30586539PubMed
534536948Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.Eur J Cancer2021https://conductscience.org/library/papers/34536948PubMed
626446948Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.Clin Cancer Res2016https://conductscience.org/library/papers/26446948PubMed
732758477Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.Lancet Oncol2020https://conductscience.org/library/papers/32758477PubMed
835621637Immune Checkpoint Inhibitors in Cancer Therapy.Curr Oncol2022https://conductscience.org/library/papers/35621637PubMed
933705549Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy.J Natl Cancer Inst2021https://conductscience.org/library/papers/33705549PubMed
1034417437Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence.Signal Transduct Target Ther2021https://conductscience.org/library/papers/34417437PubMed
1125918278Toxicities of Immunotherapy for the Practitioner.J Clin Oncol2015https://conductscience.org/library/papers/25918278PubMed
1234725502Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Nat Biotechnol2022https://conductscience.org/library/papers/34725502PubMed
1328817755Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.JAMA Oncol2018https://conductscience.org/library/papers/28817755PubMed
1431021376Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.JAMA Oncol2019https://conductscience.org/library/papers/31021376PubMed
1534761470Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis.Hepatol Res2022https://conductscience.org/library/papers/34761470PubMed
1635101302Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.Eur Urol2022https://conductscience.org/library/papers/35101302PubMed
1733764387Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.JAMA Oncol2021https://conductscience.org/library/papers/33764387PubMed
1833476593First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.Lancet Oncol2021https://conductscience.org/library/papers/33476593PubMed
1933317597The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.J Exp Clin Cancer Res2020https://conductscience.org/library/papers/33317597PubMed
2034868071Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy.Front Immunol2021https://conductscience.org/library/papers/34868071PubMed

See all 71 referencesDownload CSV of references

Cited by44

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 62 citations.

PMIDTitleJournalYearIn PapersSource
42958364Immune checkpoints: cross-disease insights and clinical dilemmas.Biomark Res2026https://conductscience.org/library/papers/42958364PubMed
42913630Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade.Cell2026https://conductscience.org/library/papers/42913630PubMed
42740907Avoidance of cardiac toxicity during the application of immune checkpoint inhibitors: a safety systematic review combining network meta-analysis and pharmacovigilance study.Front Immunol2026https://conductscience.org/library/papers/42740907PubMed
42713225Therapeutic mRNA vaccines for lung cancer: reshaping the tumor microenvironment to enhance anti-tumor immunity.Front Immunol2026https://conductscience.org/library/papers/42713225PubMed
42568649The real-world safety profile of enfortumab vedotin with or without pembrolizumab: insights from a comparative analysis of FAERS.Front Immunol2026https://conductscience.org/library/papers/42568649PubMed
42496605Pharmacovigilance Evaluation of Noninfectious Myocarditis and Pericarditis in Immune Checkpoint Inhibitor Recipients Using FAERS.Technol Cancer Res Treat2026https://conductscience.org/library/papers/42496605PubMed
42495626Integrative analysis of FAERS, network toxicology, and Mendelian randomization identifies potential targets in paclitaxel-associated systemic sclerosis.Front Immunol2026https://conductscience.org/library/papers/42495626PubMed
42370183Understanding immune checkpoint inhibitors-related myocarditis: Mechanisms and targeted therapeutic pathways.Theranostics2026https://conductscience.org/library/papers/42370183PubMed
42256063Rational design of a V-shaped DNA-targeted photosensitizer enables endogenous DNA damage-driven cGAS-STING activation and systemic antitumor immunity.Mater Today Bio2026https://conductscience.org/library/papers/42256063PubMed
42212151Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis.Front Immunol2026https://conductscience.org/library/papers/42212151PubMed
42079638Dynamic changes in gut microbiota and metabolites in advanced lung cancer patients with immune-related adverse events.Front Immunol2026https://conductscience.org/library/papers/42079638PubMed
42043855Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors.Cancer Med2026https://conductscience.org/library/papers/42043855PubMed
41972167Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database.Front Immunol2026https://conductscience.org/library/papers/41972167PubMed
41968610Endocrinologist-Led Management of Endocrine Immune-Related Adverse Events: Real-World Evidence Supporting the Japan Endocrine Society Guidelines.Cancer Med2026https://conductscience.org/library/papers/41968610PubMed
41858812Comparative Safety Analysis of Hydromorphone and Morphone Sulfate: Evidence from the 2004-2024 FAERS.J Pain Res2026https://conductscience.org/library/papers/41858812PubMed
41774718Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS.PLoS One2026https://conductscience.org/library/papers/41774718PubMed
41754815Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors: A Scoping Review.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/41754815PubMed
41629133Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system.J Immunother Cancer2026https://conductscience.org/library/papers/41629133PubMed
41565210Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system.Eur Heart J Cardiovasc Pharmacother2026https://conductscience.org/library/papers/41565210PubMed
41261920Circadian rhythm in immunotherapy and cellular therapy: impacts on the tumor microenvironment.Acta Biochim Biophys Sin (Shanghai)2026https://conductscience.org/library/papers/41261920PubMed

See all 44 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ARID1A8289PubTator's text mininghttps://conductscience.org/library/genes/8289NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36600271

GET https://conductscience.org/api/papers/v1/36600271/references?page=2